by rss feed | Nov 3, 2022 | Direct Biologics, ExoFlo, FDA, FDA IND, journal club, News Feeds
I wrote recently about how political pressure on FDA Commissioner Stephen Hahn in 2020 may have helped the Texas firm Direct Biologics move their product ExoFlo forward inside the agency. Today I analyze the ExoFlo Phase I clinical trial paper used in that push on...
